-
Mashup Score: 17Paper: A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome - 23 day(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Genes, Cells and Algorithms: Novel Methods of Predicting Progression in MGUS and SMM Hematology Disease Topics & Pathways: Research, Translational Research, Bioinformatics, Genomics, Computational biology, Biological Processes, Technology and Procedures, Omics technologies Jean-Baptiste Alberge, PhD 1,2,3, Ankit K. Dutta, PhD 1,2,3 *, Andrea Poletti 1,4
Source: ash.confex.comCategories: General Medicine NewsTweet
-
Mashup Score: 6
EHA Library; Perrot A. Jun 14 2025; 4159277;
Source: library.ehaweb.orgCategories: General Medicine NewsTweet-
RT @AuclairDan: TALQ + cetrelimab (TRIMM-3 study) #EHA25 @szusmani #mmsm https://t.co/xhd8qSifnL
-
-
Mashup Score: 319th Annual Live Medical Crossfire®: Hematologic Malignancies - 3 month(s) ago
July 26, 2025
Source: www.gotoper.comCategories: General Medicine NewsTweet-
🗽Join me in NYC this summer to explore the most controversial clinical issues in the field of hematologic malignancies! Network with local experts and bring best practices back to your clinic. Register for free using my last name as a discount code: https://t.co/qVOVepShoN https://t.co/wpp0YOUWZe
-
-
Mashup Score: 0Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up Dosing - PubMed - 4 month(s) ago
Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up Dosing
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up Dosing - the MSK experience #mmsm @BloodAdvances @MSKCancerCenter @MSK_DeptOfMed @CarlynRTanMD et al. https://t.co/KFhyLAz76z
-
-
Mashup Score: 1Login - Integrity CE - 6 month(s) ago
Username* Password* Remember me Register | Forgot Password
Source: integrityce.comCategories: General Medicine News, Hem/OncsTweet-
RT @SoMeCME: 6/ We hope you enjoyed this #MMBrief! Complete the posttest & evaluation here 👉 https://t.co/iK4QKBGsaM & claim your 🆓 CME!…
-
-
Mashup Score: 1Belantamab + Standard of Care for Newly Diagnosed Myeloma (DreaMM-9) | Saad Usmani, MD | #ASH24 - 6 month(s) ago
Dr Saad Usmani discusses a study looking at belantamab combined with the standard of care for newly diagnosed multiple myeloma. Link to ASH playlist: https:/…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
RT @MyelomaTeacher: Belantamab + Standard of Care for Newly Diagnosed Myeloma (DreaMM-9) | ... https://t.co/DRyxbkdVQU @szusmani @MSKCanc…
-
-
Mashup Score: 8Paper: Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee - 7 month(s) ago
Program: Oral and Poster Abstracts Session: 907. Outcomes Research: Plasma Cell Disorders: Poster III Hematology Disease Topics & Pathways: Adult, Bispecific Antibody Therapy, Biological therapies, Treatment Considerations, Adverse Events, Study Population, Human Carlyn Rose Tan, MD 1, Sireesha Asoori, MBBS, MPH 2 *, David Nemirovsky 3 *, Andriy Derkach, PhD 3 *, Larissa Brunaldi 4 *, Rakesh Popat 5, Chris Lau 5 *, Efstathios Kastritis, MD 6 *, Joaquín Martínez-Lopez 7 *, Radhika Bansal, MBBS 4 *, Andre
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
@VincentRK The IMWG RWE papers are in the works , being presented here at #ASH24 as well @CarlynRTanMD @HiraSMian @TomBmt133 @YiLinMDPhD et al, first ones with Tec. https://t.co/OgEHzGEolJ https://t.co/ShSU9ngmgU
-
-
Mashup Score: 12
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA Hematology Disease Topics & Pathways: Research, Clinical trials, Antibody Therapy, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies Marc S. Raab, M.D. 1 *, Niels Weinhold, PhD 2 *, K. Martin Kortüm, MD 3 *, Jan Krönke, MD 4,5, Lilli Podola 6 *, Uta Bertsch, MD 6 *, Jan H. Frenking, MD 2 *, Julia Mersi, MD 7 *,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
- 493 Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial https://t.co/5MtpL2UkzX - 494 Phase 3 Study of Teclistamab (Tec) in Combination… https://t.co/wARGeRry8W
-
-
Mashup Score: 11
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond Hematology Disease Topics & Pathways: Research, Clinical trials, Clinical Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies Gordon Cook, PhD, DSc 1,2 *, Charlotte Pawlyn, PhD 3, Kara-Louise Royle 4 *, Ethan R Senior 5 *, Dax Everritt 6 *, Jenny Bird 7 *, Stella Bowcock 8 *, Bryony Dawkins, MSc 9 *, Mark Drayson 10 *, Sharon Gillson,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
- 673 IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial https://t.co/kKMlFqbifx - 769 Isatuximab, Lenalidomide, Bortezomib and… https://t.co/tgdSdi5UrC
-
-
Mashup Score: 5
Program: Oral and Poster Abstracts Type: Oral Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Uncovering New Targets and Disease Mechanisms in Myeloma Hematology Disease Topics & Pathways: Research, Translational Research, Genomics, Biological Processes, Pathogenesis Kylee H Maclachlan, PhD, BSc, FRACP, FRCPA 1, Marios Papadimitriou 2 *, Patrick Blaney, MS 3 *, Tala Shekarkhand, MS 4 *, Timothy R. Chu, MS 5 *, Alexandra Maria Poos, PhD 6 *, Elizabeth Brown 7 *, Antje
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
- 766 Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry https://t.co/sOL5wV1dVx - 592 Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of… https://t.co/HNzPQJHoEQ
-
**Basic/Translational Abstracts: - 1019 A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome https://t.co/oSbzH0CDX6 -358 Combination with Cytotoxic Therapy and Checkpoint Blockade Overcomes Primary Resistance to BCMA Bispecific… https://t.co/MTRou3ET7G